Tiffany Thorn
Fondateur chez BIVICTRIX THERAPEUTICS PLC
Fortune : 257 951 $ au 30/06/2024
Profil
Tiffany Thorn is the founder and currently serves as the Chief Executive Officer & Executive Director at BiVictriX Therapeutics Plc, a company she founded in 2016.
She previously held the position of Chief Executive Officer & Director at Motif Bio Plc.
Ms. Thorn graduated from The University of Manchester with a graduate degree and from the University of Lancaster with an undergraduate degree.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 1 632 500 ( 1,98% ) | 257 951 $ | 30/06/2024 |
Postes actifs de Tiffany Thorn
| Sociétés | Poste | Début |
|---|---|---|
| BIVICTRIX THERAPEUTICS PLC | Fondateur | 01/01/2016 |
Anciens postes connus de Tiffany Thorn
| Sociétés | Poste | Fin |
|---|---|---|
| MOTIF BIO PLC | Directeur Général | - |
Formation de Tiffany Thorn
| The University of Manchester | Graduate Degree |
| University of Lancaster | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIVICTRIX THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
